Pharma Insight Briefings

Area of presentation – InnoPack packaging - How to deliver sterile eye drops with a safer alternative to preservatives?  

Speaker Name: Ms. Faustine MUNOZ - Global Category Manager for Ophthalmic

  1. What are the current global trends driving the pharmaceutical sector you are working in? How does your company respond to those trends?

A significant patient population requires the long term use of eye drops multiple times a day. Maintaining the sterility of eye drops is important for patient health. The use of preservatives can cause allergies or ocular irritation, and some can even cause a toxic response, damaging patients’ eyes. For chronic eye diseases such as Dry Eyes and Glaucoma, patients really need preservative-free formulations. Single use doses are expensive and preservatives can cause allergies and irritation, but the intelligent design of multi-dose bottles provides a viable means of delivering safe, preservative free eye drops. At Nemera, we take care of developing products that can make patients’ life easier with as little side effects as possible. Nemera is designing and developing products that comply with patients’ needs, such as a safe preservative-free multi-dose eye dropper without using any sterile filter. Thanks to our new technology, patients no longer suffer ANY side effects from preservatives.

2. What are the top challenges faced by the pharmaceutical sector you represent at this moment? How does your company deal with these challenges?

The ophthalmic sector is switching to preservative-free formulations and to multi-dose bottles. Our role is to offer products that patients need.
For this reason, Nemera is driving these trends proposing the best-in-class preservative-free ophthalmic multi-dose, Novelia®.
Our technology provides a safer alternative to filters: all the critical components linked to the sterility of the device are 100% controlled on line by air testing, ensuring that each single device released is safe for use by patients. The Quality by Design process is integrated in the production of our device.

3. What topic are you presenting at the Pharma Insight Briefings and why is this subject so important to the market at this time?

Our topic will present an overview of the ophthalmic market and trends, especially for the preservative-free solutions. Today most of the multi-dose eye droppers contain preservatives that damage the eyes. Preservative free formulations are better for patient health and we will explain you why. A preservative-free alternative would be the unit-dose eye droppers, but they are too costly and inconveniently bulky to make them suitable for home use for chronic conditions. Single unit preservative free drops have been calculated to be 1169% more expensive to produce than the equivalent preserved eye drops in a multi-dose bottle. We will show you that there is an alternative way to keep eye droppers clean by the intelligent use of technology. Rather than relying on the anti-microbial properties of preservatives to kill any bacteria that enter the bottle, the ideal approach is to prevent any entry of bacteria into the bottle in the first place. Finally, we will present a concrete case study, focusing on this alternative and explaining how the Quality by Design could be integrated in the manufacturing process.

4. What can attendees to your session expect to gain and which challenges does this content address? Why should they include your presentation in their agenda?

Pharmaceutical professionals should attend our presentation if they would like to have information on the ophthalmic market, the ophthalmological trends understand how intelligent design can be used to prevent the entry of bacteria into a bottle, making it possible to deliver safe preservative-free eye drops in a multi-dose bottle.

5. How do you see your sector of the market evolving in the next 5 years?

All Key Opinion Leaders agree on the danger of preservatives.

Preservative-free multi-dose eye dropper’s growth is expected to mostly come from the switch from preserved multi-dose rather than from Unit-dose.

Europe was first switching to preservative-free multi-dose bottles, followed by Latin America, Asia and now US. We see a significant and positive growth in the next 5 years in all regions.